Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DN001 recombinant botulinum toxin type A for moderate-to-severe glabellar lines
CTR20243238Phase 2Completed
- Sponsor
- Dixin Chenke Biotech
- Start
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of DN001 in glabellar furrowing, sponsored by Dixin Chenke Biotech. Started Aug 2024; status: completed.
02
Drugs
DN001
03
Conditions
glabellar furrowing
Beyond the preview
Go deeper on CTR20243238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243238.